National yearly cost of breast cancer screening in the USA and projected cost of advocated guidelines: a simulation study with life table modelling
The cost of screening varies significantly by guideline (US$8B-US$30B) and was most influenced by participation rates, high-risk population proportions and technology costs. Future work can investigate whether risk-based screening strategies being tested in ongoing clinical trials can reduce national screening costs while improving outcomes.Cite Now.
Authors
- Leslie Wilson (ORCID: https://orcid.org/0000-0002-3305-8730)
- Kierstin Catlett
- Jeffrey A. Tice
- Yiwey Shieh (ORCID: https://orcid.org/0000-0002-0159-7748)
- James Staib
- Stacey DaCosta Byfield (ORCID: https://orcid.org/0000-0001-8923-0643)
- Rashna Soonavala (ORCID: https://orcid.org/0000-0002-2109-6668)
- Kimberly Badal (ORCID: https://orcid.org/0000-0001-7776-0831)
- Laura J. Esserman (ORCID: https://orcid.org/0000-0001-9202-4568)
- Martin Eklund (ORCID: https://orcid.org/0000-0001-5032-5266)
- Liz Maffey
- Mi‐Ok Kim (ORCID: https://orcid.org/0000-0002-7712-3653)
Institutions
- University of California, San Francisco (US)
- Cornell University (US)
- Karolinska Institutet (SE)
- Optum (United States) (US)
- UnitedHealth Group (United States) (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-089428
- Citations
- 3
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 3.14